Pinterest Inc vs uniQure N.V. Ordinary Shares — how do they compare? Pinterest Inc trades at $21.75 (market cap $12.32B), while uniQure N.V. Ordinary Shares trades at $20.67 (market cap $1.45B). The key difference: Pinterest Inc is far larger — about 8.5× uniQure N.V. Ordinary Shares's market cap, and Pinterest Inc is trading nearer its 52-week high, uniQure N.V. Ordinary Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Pinterest Inc for 85 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| PINS | QURE | |
|---|---|---|
Market Cap | $12.32B | $1.45B |
Volume | 10,523,209 | 3,323,243 |
Sector | Media | Health |
52-Week High | $35.24 | $70.59 |
52-Week Low | $15.42 | $9.03 |
Typical Hold Time | 85 Days | 0 Days |
Enterprise Value | $12.24B | $707.46M |
Signals from Pluang's Aura AI — not financial advice
Pinterest (PINS) trades at $22.36, up 4.37% today, showing strong momentum after recent earnings beats. The stock maintains a bullish technical outlook with consistent revenue growth from $2.8B in 2022 to $4.2B in 2025. Analyst consensus is strongly positive with 54% buy ratings and a $27.93 price target, representing 25% upside potential. Recent news highlights Pinterest's visual search ads launch and international monetization growth as key catalysts.
The outlook remains favorable with strong fundamentals and technical momentum, though elevated valuation ratios (P/E 65.8) and insider selling present near-term risks. Revenue growth continues at 15%+ annually while profit margins improved from negative to 9.9% in 2025. Competition in digital advertising and market volatility are key watchpoints for investors.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Pinterest is an online product and idea discovery platform that helps users gather ideas on everything from recipes to cook to destinations to travel to. Founded in 2010, the platform consists of a largely female audience, at roughly two thirds of its more than 365 million monthly active users. The company generates revenue by selling digital ads and is now rolling out more in-platform e-commerce features.
Read more on PINS →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →